Inactive Instrument

Highlights Cellular Biomedicine Group, Inc.

Equities

CBMG

US15117P1021

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate Nktr-255 in Combination with C-Til051 in Advanced Non-Small Cell Lung Cancer	23-09-27	CI
Cellular Biomedicine Group Announces FDA Clearance of Investigational New Drug Application for Novel TIL Therapy C-TIL051	22-10-31	CI
Cellular Biomedicine Group Inc Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma	22-01-12	CI
Cellular Biomedicine Group Inc. Receives FDA Clearance of IND Application for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	21-12-13	CI
Cellular Biomedicine : Completes Merger with CBMG Holdings; Shares to No Longer Trade on Nasdaq	21-02-19	MT
Cellular Biomedicine Group :, Inc. Announces Completion of Merger	21-02-19	PR
A consortium of buyers completed the acquisition of remaining 52.34% stake in Cellular Biomedicine Group, Inc. from a group of shareholders.	21-02-18	CI
Cellular Biomedicine : CBMG Stockholders Approve Merger	21-02-08	PU
Cellular Biomedicine Group :, Inc. Stockholders Approve Merger	21-02-08	PR
Cellular Biomedicine : Leading Proxy Advisory Firms Glass Lewis and ISS Recommend CBMG Stockholders Vote FOR Proposed Merger	21-01-29	PU
Glass Lewis and Institutional Shareholder Recommend Cellular Biomedicine Group Stockholders Vote For Proposed Merger	21-01-28	CI
Cellular Biomedicine : Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed Merger	21-01-28	PR
Cellular Biomedicine Group, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-09	CI
Cellular Biomedicine : Enters Into Definitive Merger Agreement, Transaction Would Result In Company Going Private	20-08-13	AQ
Cellular Biomedicine Group, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-12	CI
Cellular Biomedicine Group : (CBMG) Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private	20-08-12	PR
Cellular Biomedicine Group, Inc. Provides Updates to Clinical Programs	20-07-13	CI
Cellular Biomedicine Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-06	CI
Cellular Biomedicine Group to Expand its Footprint in Maryland	20-02-28	CI
Cellular Biomedicine Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-02-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cellular Biomedicine Group, Inc.

Equities

CBMG

US15117P1021

Highlights

Filters